Drugs plus ligation to prevent rebleeding in cirrhosis: An updated systematic review

Liver International

Volumn 34, Issue 6, 2014, Pages 823-833

  Puente, Angela ^a   Hernández Gea, Virginia ^a   Graupera, Isabel ^a   Roque, Marta ^a   Colomo, Alan ^a,b   Poca, Maria ^a   Aracil, Carles ^c   Gich, Ignasi ^a   Guarner, Carlos ^a,b   Villanueva, Càndid ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Combined therapy; Meta analysis; Variceal ligation; Variceal rebleeding; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL; PROPRANOLOL; PROTON PUMP INHIBITOR; SUCRALFATE; HEMOSTATIC AGENT; ISOSORBIDE DINITRATE;

BLEEDING; ENDOSCOPIC SURGERY; ENDOSCOPIC VARICEAL LIGATION; ESOPHAGUS ULCER; HUMAN; LIGATION; LIVER CIRRHOSIS; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VARICEAL REBLEEDING; ANALOGS AND DERIVATIVES; ANIMAL; CHI SQUARE DISTRIBUTION; COMPLICATION; DRUG COMBINATION; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; RISK; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEMOSTATIC TECHNIQUES; HEMOSTATICS; HUMANS; ISOSORBIDE DINITRATE; LIGATION; LIVER CIRRHOSIS; ODDS RATIO; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84902548832     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12452     Document Type: Review

References (43)

1. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
2. De Franchis R, Primignani M. Endoscopic treatment for portal hypertension. Semin Liver Dis 1999; 19: 439-55.
3. Laine L, Cook D. Endoscopic ligation compared with sclerothepary for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123: 280-7.
4. Singh P, Pooran N, Indaram A, Bank S. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis. Am J Gastroenterol 2002; 97: 623-9.
5. Karsan HA, Morton SC, Shekelle PG, et al. Combination endoscopic band ligation and sclerotherapy compared with endoscopic band ligation alone for the secondary prophylaxis of esophageal variceal hemorrhage: a meta-analysis. Dig Dis Sci 2005; 50: 399-406.
6. Garcia-Pagán JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114: 869-73.
7. Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31: 1239-45.
8. Villanueva C, Balanzó J, Novella M, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624-9.
9. Ding SH, Liu J, Wang JP. Efficacy of β-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis. World J Gastroenterol 2009; 15: 2151-5.
10. Cheung J, Zeman M, Van Zanten SV, Tandon P. Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices. Aliment Pharamcol Ther 2009; 30: 577-88.
11. Li L, Yu C, Li Y. Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol 2011; 25: 147-55.
12. Lo GH, Chen WC, Lin CK, et al. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology 2008; 48: 580-7.
13. Garcia-Tsao G, Sanyal A, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases, the Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-38.
14. De Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8.
15. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000; 32: 461-565.
16. De la Peña J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 572-8.
17. Gonzalez R, Zamora J, Gomez-Camarero J, et al. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008; 149: 109-22.
18. Kumar A, Jha SK, Sharma P, et al. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 2009; 137: 892-901.
19. Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicenter randomized controlled trial. Gut 2009; 58: 1144-50.
20. Lo GH, Chen WC, Chan HH, et al. A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. J Gastroenterol Hepatol 2009; 24: 982-7.
21. Lo GH, Hernández-Gea V, Aracil C, Villanueva C. Management of varices in cirrhosis. N Engl J Med 2010; 362: 2331-3.
22. Villanueva C, Miñana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol plus isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647-55.
23. Patch D, Sabin CA, Goulis J, et al. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gatroenterology 2002; 123: 1013-9.
24. Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal bleeding. Gastroenterology 2002; 123: 728-34.
25. El-Tahawy M, Mahmoud S, Waked I, Selim K, Hassanein T. Band ligation versus medical therapy in prevention of variceal rebleeding: a randomized controlled study in schistosomal hepatic fibrosis and HCV coinfection. Gastyroenterol 2003; 124: A663-4.
26. Sarin SK, Wadhawan M, Gupta R, et al. Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci 2005; 50: 1538-47.
27. Shiha G, Menesy A, Seef S, et al. Endoscopic ligation compared with propranolol and combined isosorbide mononitrate (ISMN) and propranolol to prevent recurrent variceal bleeding: a prospective randomized trial. Gut 2005; 54(Suppl. 2): A6.
28. Romero G, Kravetz D, Argonz J, et al. Comparative study between nadolol and 5-isosorbide mononitrate vs endoscopic band ligation plus slerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. Aliment Pharmacol Ther 2006; 24: 601-11.
29. Ahmad I, Khan AA, Alam A, et al. Propranolol, isosorbide mononitrate and endoscopic band ligation - alone or in varying combinations for the prevention of esophageal variceal rebleeding. J Coll Physicians Surg Pak 2009; 19: 283-6.
30. Sollano JD, Melchor RJ, Chan M, Ismael AE. Propranolol prevents rebleeding after variceal ligation. Gastroinets Endosc 2002; 53: AB143.
31. Villanueva C, Aracil C, Colomo A, et al. Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol+ligation vs hepatic venous pressure gradient-guided pharmacological therapy. Alimen Pharmacol Ther 2009; 29: 397-408.
32. Cheng WF, Shi RH, Chen XX, Ding J. Effects of propranolol on rebleeding following endoscopic esophageal variceal ligation: a prospective, controlled trial. World Chin J Digestol 2009; 17: 83-5.
33. Abdel-Rhaim AY, Abdel-Ghany MS, El-Kholy B. Band ligation alone versus band ligation and propranolol in the management of bleeding esophageal varices. Am J Gastroenterol 2000; 95: 2442.
34. Ravipati M, Katragadda S, Swaminathan PD. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. Gastrointes Endosc 2009; 70: 658-64.
35. D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 1611-24.
36. Albillos A, Bañares R, González M, Ripoll C, Gonzalez R. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007; 102: 1116-26.
37. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.
38. Villanueva C, López-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004; 40: 757-65.
39. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey - the case for nonselective β-blockers. Gastroenterology 2007; 133: 2029-36.
40. García-Pagán JC, Bosch J. Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 526-35.
41. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding - unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology 2008; 47: 1764-72.
42. Bañares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatoloy 2002; 36: 1367-73.
43. Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010; 53: 558-67.